Published in Exp Hematol Oncol on June 13, 2014
Phase l/II Study of Ruxolitinib for Acute Leukemia | NCT01251965
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget (2014) 0.89
Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized. J Hematol Oncol (2016) 0.81
Drugging the unfolded protein response in acute leukemias. J Hematol Oncol (2015) 0.79
The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. Int J Oncol (2016) 0.76
Association Between RFC1 G80A Polymorphism and Acute Lymphoblastic Leukemia: a Review and Meta-Analysis of 10 Studies. Iran J Ped Hematol Oncol (2016) 0.75
Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome. PLoS One (2016) 0.75
The complex translocation (9;14;14) involving IGH and CEBPE genes suggests a new subgroup in B-lineage acute lymphoblastic leukemia. Genet Mol Biol (2016) 0.75
Novel Cryptic Rearrangements in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Involving the MLL Gene. J Histochem Cytochem (2015) 0.75
DNA methylation and leukemia susceptibility in China: Evidence from an updated meta-analysis. Mol Clin Oncol (2016) 0.75
Specific expression of novel long non-coding RNAs in high-hyperdiploid childhood acute lymphoblastic leukemia. PLoS One (2017) 0.75
High rates of submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia. Mol Cytogenet (2015) 0.75
Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia. Cancer Cell Int (2015) 0.75
A novel IGH@ gene rearrangement associated with CDKN2A/B deletion in young adult B-cell acute lymphoblastic leukemia. Oncol Lett (2016) 0.75
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Br J Cancer (2017) 0.75
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell (1996) 9.74
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Acute lymphoblastic leukaemia. Lancet (2008) 8.54
Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature (1999) 5.77
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol (2012) 5.08
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science (1997) 4.29
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 3.50
Acute lymphoblastic leukaemia. Lancet (2013) 3.44
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood (1996) 3.39
Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol (2010) 3.02
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood (2010) 2.25
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia (2009) 2.11
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2012) 2.09
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J (1997) 2.06
Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood (2006) 2.00
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol (2009) 2.00
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer (2005) 1.93
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood (2013) 1.91
FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2003) 1.91
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet (2013) 1.87
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood (2012) 1.78
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77
Li-fraumeni syndrome. Genes Cancer (2011) 1.77
The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol (1996) 1.75
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood (2006) 1.74
Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing. FEBS J (2010) 1.73
Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol (2013) 1.73
Biological and therapeutic aspects of infant leukemia. Blood (2000) 1.70
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood (2012) 1.66
EBF contains a novel zinc coordination motif and multiple dimerization and transcriptional activation domains. EMBO J (1995) 1.57
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood (2007) 1.56
High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer (2009) 1.49
Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature (2014) 1.49
Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia (2008) 1.48
Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood (2011) 1.48
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood (2012) 1.47
The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev (2012) 1.47
Clonal evolution of acute leukemia genomes. Oncogene (2012) 1.46
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet (2013) 1.45
The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2012) 1.40
Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest (2012) 1.38
Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2010) 1.37
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica (2013) 1.36
Therapeutic targeting of MLL. Blood (2009) 1.36
Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun (2014) 1.33
Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol (2004) 1.30
Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia (2003) 1.28
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood (2003) 1.26
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia (2007) 1.25
Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood (2003) 1.25
Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood (1996) 1.23
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia (2013) 1.22
Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene (2013) 1.20
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood (2005) 1.20
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. J Clin Invest (2013) 1.19
CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia (2012) 1.18
Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants. Leukemia (1998) 1.16
The role of E2A-PBX1 in leukemogenesis. Oncogene (2001) 1.15
Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Blood (1999) 1.14
t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood (2007) 1.10
Rare allelic forms of PRDM9 associated with childhood leukemogenesis. Genome Res (2012) 1.09
A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia (2008) 1.08
Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program (2011) 1.08
Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood (2006) 1.07
Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers? Blood (2009) 1.06
Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup. Leukemia (2003) 1.05
Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood (1987) 1.03
Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia (2002) 1.01
Central nervous system leukemia. Pediatr Clin North Am (1988) 1.00
Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol (2008) 0.99
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol (2007) 0.98
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia (2004) 0.97
Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. Leuk Res (2010) 0.94
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep (2013) 0.91
JAK2 Translocations in hematological malignancies: Review of the literature. J Assoc Genet Technol (2010) 0.91
No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities. Leukemia (2005) 0.86
B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. Mod Pathol (2013) 0.83
The evolution of clinical trials for infant acute lymphoblastic leukemia. Blood Cancer J (2014) 0.83